INTERLEUKIN 2

INTERLEUKIN 2 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Cetus has introduced a stable rDNA interleukin-2 (rIL-2) for the treatment of renal cell carcinoma. Recent studies showed that rIL-2 in combination with lymphokine activated killer cells or tumor infiltrating lymphocytes induced regression or partial regression in patients with advanced metastatic cancers.

• Originator

  Cetus (USA)

• Indications

  IL-2 (Proleukin) is a cytokine that promotes the proliferation, differentiation, and recruitment of T and B lymphocytes, natural killer cells, and thymocytes. Human recombinant IL-2 is designated as rIL-2. rIL-2 binds to IL-2 receptors on responsive cells and induces proliferation and differentiation of T helper cells and T cytotoxic cells. It also can induce B-lymphocyte proliferation, activate macrophage activity, and augment the cytotoxicity of natural killer cells.

• Definition

  A type of biological response modifier (a substance that can improve the body’s natural response to disease). It stimulates the growth of certain disease-fighting blood cells in the immune system. Also called IL-2.

• Trademarks

  Proleukin

• Mechanism of action

  rIL-2 is administered systemically as an immunostimulating agent in patients with AIDS and to augment specific antitumor immunity. Patients with renal cell carcinoma or melanoma have been effectively treated with rIL-2 in combination with adoptive transfer immunotherapy. The latter refers to the injection of the patient’s own cytokine-activated killer cells or tumorinfiltrating lymphocytes after they reside in tissue culture for several weeks in the presence of rIL-2.

• Clinical Use

  Protein of rDNA origin that is used in treating renal cell carcinoma and metastatic malignant melanoma.

• Nebenwirkungen

  Systemic administration of rIL-2 causes fever, nausea, vomiting, fatigue, and malaise. Other adverse affects include flushing, diarrhea, chills, rash, edema, symptomatic hypotension, and certain renal abnormalities. These tend to occur at increased dosage levels and are attenuated by reducing the dosage.

INTERLEUKIN 2 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(12)Suppliers